RxDoctor Payments Data

Carlos Orces, MD

Internal Medicine · Laredo, TXNPI 1164483400

Payments from drug & device makers

$1,284in general payments, 2019–2025

Across 70 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$546
  • Johnson & Johnson$265
  • Amgen$175
  • E.r. Squibb & Sons, L.L.C.$125
  • GSK$44
  • ANI Pharmaceuticals, Inc.$31
  • plus $99 from 6 others

What the payments were for

  • Food & beverage$1,284100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,284 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$148,055
Medicare patients
217
Services billed
1,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept178$1,417,539
EnbrelEtanercept67$479,233
Cimzia (2 Pack)Certolizumab Pegol45$321,202
RinvoqUpadacitinib27$265,556
Humira(Cf) PenAdalimumab26$178,968
Xeljanz XrTofacitinib Citrate28$167,411
OzempicSemaglutide141$146,669
JardianceEmpagliflozin129$113,693
Humira PenAdalimumab15$96,569
XeljanzTofacitinib Citrate14$74,122
OtezlaApremilast14$72,282
FarxigaDapagliflozin Propanediol70$63,193
TradjentaLinagliptin46$40,146
JanumetSitagliptin Phos/Metformin Hcl21$27,471
MyrbetriqMirabegron55$26,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$175$551,51581 claims
AbbVieRinvoq, Linzess$546$275,33145 claims
AstraZenecaFarxiga$14$63,19370 claims
NovartisEntresto$13$12,24913 claims
GSKBreo Ellipta$44$6,02312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →